Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice
Table 3
Odds ratio of clinical failure in primary and secondary efficacy endpoints for intravenous FCM treatment.
Characteristic
Hemoglobin increase ≥2 g/dL
Hemoglobin increase ≥3 g/dL
Transferrin saturation >
(%)
OR (95% CI)
(%)
OR (95% CI)
(%)
OR (95% CI)
All
190 (41)
—
94 (20)
—
285 (63)
—
Male
35 (35)
1.7 (0.94–3.13)
20 (20)
1.01 (0.50–2.10)
54 (55)
1.45 (0.91–2.31)
Iron deficiency anemia
184 (40)
1.27 (0.42–3.45)
92 (24)
0.07 (0.01–0.24)
53 (69)
1.29 (0.77–2.23)
Iron deficiency without anemia
—
—
—
—
53 (69)
0.77 (0.45–1.30)
Diseases of the digestive system
79 (40)
0.88 (0.54–1.42)
43 (22)
0.57 (0.31–1.04)
123 (63)
0.95 (0.63–1.4)
Diseases of the genitourinary system
67 (55)
0.46 (0.25–0.87)
31 (26)
1.22 (0.59–2.54)
82 (68)
0.88 (0.52–1.48)
Neoplasms
12 (26)
2.19 (0.98–5.19)
5 (11)
1.63 (0.57–5.72)
30 (67)
0.70 (0.35–1.38)
Diseases of the circulatory system
11 (29)
3.34 (1.31–8.98)
6 (16)
2.1 (0.72–6.86)
18 (47)
1.82 (0.91–3.65)
Other diseases
21 (40)
0.94 (0.45–1.97)
9 (17)
1.12 (0.47–2.90)
32 (62)
1.13 (0.61–2.06)
Cumulative FCM treatment
500 mg
18 (15)
—
5 (4)
—
58 (51)
—
501–1000 mg
141 (49)
0.34 (0.18–0.62)
70 (24)
0.36 (0.12–0.92)
189 (65)
0.57 (0.36–0.88)
1001–3000 mg
31 (66)
0.19 (0.07–0.49)
19 (40)
0.23 (0.06–0.73)
38 (81)
0.25 (0.10–0.55)
Significant odds ratio in boldface; CI: confidence interval; FCM: ferric carboxymaltose; OR: odds ratio; N = 450, only patients who had transferrin saturation <20% before treatment were considered for this endpoint. Reference group: cumulative iron dose of 500 mg.
